Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Marina Y. Konopleva"'
Autor:
Tapan M. Kadia, Patrick K. Reville, Xuemei Wang, Caitlin R. Rausch, Gautam Borthakur, Naveen Pemmaraju, Naval G. Daver, Courtney D. DiNardo, Koji Sasaki, Ghayas C. Issa, Maro Ohanian, Guillermo Montalban-Bravo, Nicholas J. Short, Nitin Jain, Alessandra Ferrajoli, Kapil N. Bhalla, Elias Jabbour, Koichi Takahashi, Rashmi Malla, Kelly Quagliato, Rashmi Kanagal-Shamanna, Uday R. Popat, Michael Andreeff, Guillermo Garcia-Manero, Marina Y. Konopleva, Farhad Ravandi, Hagop M. Kantarjian
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 40(33)
PURPOSE The combination of venetoclax and 5-azacitidine (5-AZA) for older or unfit patients with acute myeloid leukemia (AML) improves remission rates and survival compared with 5-AZA alone. We hypothesized that the addition of venetoclax to cladribi
Autor:
Courtney D. DiNardo, Curtis A. Lachowiez, Koichi Takahashi, Sanam Loghavi, Tapan Kadia, Naval Daver, Lianchun Xiao, Maria Adeoti, Nicholas J. Short, Koji Sasaki, Sa A. Wang, Gautam Borthakur, Ghayas Issa, Abhishek Maiti, Yesid Alvarado, Naveen Pemmaraju, Guillermo Montalban Bravo, Lucia Masarova, Musa Yilmaz, Nitin Jain, Michael Andreeff, Guillermo Garcia‐Manero, Steven Kornblau, Farhad Ravandi, Elias Jabbour, Marina Y. Konopleva, Hagop M. Kantarjian
Publikováno v:
American journal of hematologyREFERENCES. 97(8)
Background: Multiagent induction chemotherapy consisting of fludarabine, cytarabine, G-CSF, and idarubicin (FLAG-IDA) results in complete remission in ~ 85% of newly diagnosed patients with acute myeloid leukemia (ND-AML), yet 30-40% experience relap
Autor:
Chong Chyn Chua, Danielle Hammond, Andrew Kent, Ing Soo Tiong, Marina Y. Konopleva, Daniel A. Pollyea, Courtney D. DiNardo, Andrew H. Wei
Publikováno v:
Blood advances. 6(13)
The clinical benefit of adding venetoclax (VEN) to hypomethylating agents or low-dose cytarabine in older and/or unfit patients with newly diagnosed acute myeloid leukemia (AML) has been confirmed in phase 3 studies. With the increased uptake of VEN-
Autor:
Patrick K, Reville, Koji, Sasaki, Hagop M, Kantarjian, Naval G, Daver, Musa, Yilmaz, Courtney D, Dinardo, Nicholas J, Short, Gautam, Borthakur, Naveen, Pemmaraju, Rohtesh S, Mehta, Sherry, Pierce, Sergej N, Konoplev, Joseph D, Khoury, Guillermo, Garcia-Manero, Marina Y, Konopleva, Elias, Jabbour, Farhad, Ravandi, Tapan M, Kadia
Publikováno v:
Am J Hematol
Mutations in in fms-like tyrosine kinase 3 (FLT3) gene are common genomic alterations in acute myeloid leukemia (AML). FLT3 internal tandem duplication mutations (FLT3-ITD) have consistently been shown to be adversely prognostic, particularly those w
Autor:
Michael E, Rytting, Deborah A, Thomas, Susan M, O'Brien, Farhad, Ravandi-Kashani, Elias J, Jabbour, Anna R, Franklin, Tapan M, Kadia, Naveen, Pemmaraju, Naval G, Daver, Alessandra, Ferrajoli, Guillermo, Garcia-Manero, Marina Y, Konopleva, Jorge E, Cortes, Gautham, Borthakur, Rebecca, Garris, Maria, Cardenas-Turanzas, Kurt, Schroeder, Jeffrey L, Jorgensen, Steven M, Kornblau, Hagop M, Kantarjian
Publikováno v:
Cancer. 120(23)
Various trials have reported improved outcomes for adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL) who received treatment with pediatric-based regimens. Those reports prompted the current investigation of the pediatric aug